Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/30119
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNaba, NM-
dc.contributor.authorTolay, N-
dc.contributor.authorErman, B-
dc.contributor.authorSayi Yazgan, A-
dc.date.accessioned2024-11-14T09:18:55Z-
dc.date.available2024-11-14T09:18:55Z-
dc.date.issued2020-01-
dc.identifierORCiD: Ayça Sayi Yazgan https://orcid.org/0000-0002-9015-8244-
dc.identifier.citationNaba, N.M. et al. (2020) 'Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells', Turkish Journal of Biology, 44 (1), pp. 15 - 23. doi: 10.3906/biy-1909-12.en_US
dc.identifier.issn1300-0152-
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/30119-
dc.description.abstractOne of the most challenging problems in colorectal cancer (CRC) is resistance to chemotherapy drugs such as doxorubicin (DOX). The programmed death ligand-1 (PD-L1) is related to chemoresistance and is overexpressed in several human cancer cell types. Here, we investigated the changes in the expression of PD-L1 in DOX-treated CRC and breast cancer (BRC) cells. Also, to address PD-L1 regulation, we assessed expression levels of miR-140 and miR-34a, two microRNAs that can target the 3’ UTR region of the gene encoding PD-L1. HCT116 CRC and MDA-MB-231 BRC cells were treated with various doses of DOX in culture and PD-L1 expression was quantified using qRT-PCR, flow cytometry, and western blot analysis. We also evaluated PD-L1 localization in HCT116 cells by immunofluorescence. Next, we assessed expression of miR-140 and miR-34a in DOX-treated HCT116 and MDA-MB-231 cells. Finally, we investigated whether miR-140 targets the 3’ UTR of the gene encoding PD-L1 in HCT116 cells using the p2FP-RNAi RNAi reporter vector system. PD-L1 expression in HCT116 cells, while low at baseline, can be induced by treatment with 0.5 µM DOX. MDA-MB-231 baseline PD-L1 expression exceeded HCT116 cell maximal expression and decreased following DOX treatment. We further demonstrated that PD-L1 localizes to the cell surface in DOX-treated HCT116 cells. While miR-140 expression decreased in DOX-treated HCT116 cells, it increased in DOX-treated MDA-MB-231 cells. MiR-34a expression increased in both DOX-treated cell types. Finally, we present evidence for the regulation of PD-L1 by miR-140 in HCT116 cells. PD-L1 expression can increase following treatment with DOX in HCT116 cells but decrease in MDA-MB-231 cells, suggesting a distinct response to DOX in these two different cancer types. Also, a negative correlation between PD-L1 and miR-140 was observed in DOX-treated HCT116 cells, but not in MDA-MB-231 cells.en_US
dc.description.sponsorshipThis study was supported by İstanbul Technical University, Department of Scientific Research Projects (ITÜ-BAP) (Project # 39555).-
dc.format.extent15 - 23-
dc.format.mediumPrint-Electronic-
dc.language.isoenen_US
dc.publisherTUBITAK Academic Journalsen_US
dc.rightsAttribution 4.0 International-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectPD-L1en_US
dc.subjectdoxorubicinen_US
dc.subjectmiR-34aen_US
dc.subjectmiR-140en_US
dc.titleDoxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cellsen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.3906/biy-1909-12-
dc.relation.isPartOfTurkish Journal of Biology-
pubs.issue1-
pubs.publication-statusPublished-
pubs.volume44-
dc.identifier.eissn1303-6092-
dc.rights.licensehttps://creativecommons.org/licenses/by/4.0/legalcode.en-
dc.rights.holderThe Author(s)-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2020 The Author(s). This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).1.61 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons